The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38661186.
- Also identified by DOI 10.1093/cid/ciae229 and PMC identifier 12098015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report identification of 5 patients with infections caused by NDM-5-producing Escherichia coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management.
Medical subject headings
- Escherichia coli
- beta-Lactamases
- Microbial Sensitivity Tests
- Anti-Bacterial Agents
- Escherichia coli Infections
- Penicillin-Binding Proteins
- Mutation
- Azabicyclo Compounds